Celyad enters license agreement for C-Cure in Greater China

31 August 2015

Belgian biotech company Celyad (Euronext Brussels: CYAD) has entered into a new collaboration and distribution agreement with its Hong-Kong based partner, Medisun International.

This license agreement confirms Celyad’s intention to expand the global footprint of its lead cardiac disease cell therapy candidate for the treatment of ischemic heart failure, C-Cure.

The company’s shares gained 3.8% to 45.00 euros by around midday on Monday following the announcement. Analysts have set a one year consensus price target of $87.50 for the company and are forecasting that the company will post ($0.74) earnings per share for the current quarter, according to Zacks Equity Research. Zacks has also given Celyad an industry rank of 98 out of 265 based on the ratings given to its competitors.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK